source
- New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budgetThe FDA has approved daraxonrasib, a therapy from Revolution Medicines that targets the KRAS mutation in pancreatic cancer. The drug is intended for patients who have already received treatment and…
- Experts see Replimune’s Tudriqev approval as a step toward broader use of localized cancer therapiesReplimune received FDA approval last month for Tudriqev, an oncolytic virus injected directly into melanoma tumors, marking only the second such approval for a therapy delivered straight into a tum…